The Ultimate Guide to Women’s Sexual Health, Hormone Replacement Therapy (HRT) & Menopause

What It Covers

Dr. Rachel Rubin, board-certified urologist and sexual medicine specialist, explains how hormone fluctuations affect women from puberty through menopause, covering the genitourinary syndrome of menopause (GSM), vaginal hormone therapy, HRT history, testosterone deficiency in women, and why decades of medical misinformation have left millions of women undertreated, suffering preventable UTIs, painful sex, bladder dysfunction, and hormonal decline.

Key Questions Answered

• •Vaginal Hormones & UTI Prevention: Microdosed vaginal estrogen cream — applied twice weekly, costing as little as $7/month — reduces urinary tract infections by more than 50%. This applies to women of all ages, including those on birth control, breastfeeding, or post-menopausal. Generic estradiol cream runs approximately $13 per tube, lasting roughly 2.5 months. A 2025 American Urological Association guideline formally recommends this as standard care, yet only 9% of eligible Medicare patients currently receive a prescription.
• •GSM Affects All Ages, Not Just Menopause: Genitourinary Syndrome of Menopause (GSM) occurs whenever hormones drop or fluctuate — during breastfeeding, on birth control pills, on acne medications like spironolactone, or during perimenopause. Symptoms include urinary frequency, urgency, leakage, dryness, painful sex, and recurrent UTIs. A 20-year-old on oral contraceptives can develop GSM because birth control suppresses testosterone and disrupts vaginal pH, altering the microbiome and increasing infection susceptibility.
• •Vaginal Hormones Are Separate From Systemic HRT: Vaginal estrogen is microdosed and localized — it does not circulate systemically. A woman with zero baseline estrogen who uses vaginal estrogen sees her levels rise only to approximately 20 for a few hours before returning to zero, comparable to average male estrogen levels. Women already on systemic hormone therapy (patches, pills, pellets) still require separate vaginal hormone treatment, as systemic doses are insufficient to resolve GSM symptoms per AUA Guideline Statement 11.
• •The 2002 Women's Health Initiative Distorted HRT for Decades: A single NIH press conference in 2002 — held before the study published — declared hormones caused breast cancer and cardiovascular disease, triggering an FDA black-box warning on all hormone products. Prescriptions collapsed overnight. The study examined one specific oral hormone formulation; the warning was incorrectly applied to patches, progesterone, and vaginal hormones. In February 2026, the FDA officially removed black-box warnings from vaginal hormone products, a change advocates had pursued for over two decades.
• •Testosterone Deficiency in Women Starts in the Thirties: Women's testosterone begins declining in their mid-thirties — unrelated to menopause — causing low libido, reduced arousal, weaker orgasms, low energy, mood changes, and increased UTI susceptibility. No FDA-approved testosterone product exists for women in the US, though global consensus guidelines confirm its safety and efficacy. Clinicians can prescribe generic male testosterone gel at approximately one-tenth the male dose (~$8/month), applied daily to the thigh. Effects typically emerge at four to six months.
• •Vaginal pH Testing Is a Practical Self-Assessment Tool: Vaginal pH strips, available on Amazon, provide a direct indicator of hormonal and microbiome health. A healthy vaginal pH is 4.5 or below (acidic, shown as yellow-green on the strip). A high pH reading (dark blue) signals disrupted microbiome, elevated infection risk, and likely hormone deficiency. Clinicians use pH testing to verify whether prescribed vaginal hormones are being used correctly and at sufficient doses, making it a useful monitoring tool between appointments.
• •Postpartum Hormonal Collapse Is Clinically Equivalent to Menopause: During pregnancy, estrogen reaches approximately 3,000 pg/mL. Within hours of delivery, it crashes to near zero — a hormonal drop equivalent to surgical menopause. Breastfeeding extends this low-estrogen state for its entire duration. This explains postpartum brain fog, hot flashes, sleep disruption, vaginal dryness, and increased UTI frequency. Vaginal hormone therapy is safe during lactation, does not affect milk supply, and is clinically indicated yet rarely offered. A 2024 study confirmed widespread underuse in this population.